Ehlers–Danlos syndromes (EDS) are a clinically and genetically heterogeneous group of hereditary connective tissue disorders involving joint hyperlaxity, cutaneous hyperelasticity, and tissue fragility.
A revised classification containing 13 subtypes was published by the International EDS Consortium, with a number of clinical conditions to guide and improve the diagnosis of each subtype [2][1]. In the European Union, a disease is considered ‘rare’ if it affects fewer than one in two thousand people [3][2]. In the case of EDS, the prevalence varies, depending on the type: between 1:30,000 (classical type) and < 1:1,000,000 (arthrochalasia type), whereas for the rarest form (the periodontitis type), the prevalence is unknown [1][3].
EDS’ oral conditions have been described as periodontitis [2[1][4][5],4,5], temporomandibular dysfunctions [2[1][6],6], bleeding tendencies [7[7][8],8], enamel hypoplasia [2[1][9],9], shape abnormalities of the teeth and changes in the number of teeth [2[1][8],8], a high palate [2[1][10],10], dysgnathia, and malocclusion [2[1][11],11], as well as decreased effects of local anesthesia [12,13][12][13].
Details about which area the research applies to or what kind of problems it can solve. Your insights, or hypotheses if necessary, regarding the research are also welcomed.